Literature DB >> 6155177

Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent.

B Bizzini, P Grob, M A Glicksman, K Akert.   

Abstract

It has been previously demonstrated that the non-toxic B-IIb tetanus toxin-derived fragment is transported retrogradely within neurons of the rat peripheral nervous system. In the present work we have shown that when a foreign polypeptide, in this case the Ibc tetanus toxin fragment, is coupled to B-IIb by a disulfide bond, it is transported retrogradely from the axonal endings within muscle to the motoneuronal perikarya. In contrast, Ibc fragment alone was found not to be transported. From these results we draw the conclusion that fragments like B-IIb may serve as specific carriers for chemical and chemotherapeutic agents into the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155177     DOI: 10.1016/0006-8993(80)90959-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin.

Authors:  K Dobrenis; A Joseph; M C Rattazzi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Retrograde axonal transport of an exogenous enzyme covalently linked to B-IIb fragment of tetanus toxin.

Authors:  P Beaude; A Delacour; B Bizzini; D Domuado; M H Remy
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

Review 3.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

4.  Motor neurone targeting of IGF-1 prevents specific force decline in ageing mouse muscle.

Authors:  Anthony M Payne; Zhenlin Zheng; María Laura Messi; Carol E Milligan; Estela González; Osvaldo Delbono
Journal:  J Physiol       Date:  2005-11-17       Impact factor: 5.182

5.  Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system.

Authors:  L Coen; R Osta; M Maury; P Brûlet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

6.  Isolation, purification, and characterization of fragment B, the NH2-terminal half of the heavy chain of tetanus toxin.

Authors:  M Matsuda; D L Lei; N Sugimoto; K Ozutsumi; T Okabe
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

7.  Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule.

Authors:  W A Volk; B Bizzini; R M Snyder; E Bernhard; R R Wagner
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

8.  Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging.

Authors:  Dawid Schellingerhout; Lucia G LeRoux; Brian P Hobbs; Sebastian Bredow
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

9.  Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.

Authors:  Aaron G Filler; Garth T Whiteside; Mark Bacon; Martyn Frederickson; Franklyn A Howe; Miri D Rabinowitz; Alan J Sokoloff; Terrence W Deacon; Chris Abell; Raj Munglani; John R Griffiths; B Anthony Bell; Andrew M L Lever
Journal:  BMC Neurosci       Date:  2010-01-20       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.